Christopher Yea - 08 Jul 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Reporting relationship: CHIEF DEVELOPMENT OFFICER
Issuer ticker: KALV
Reported as of: 08 Jul 2025
Net transaction value: -$474,698
SEC form: 4
Accepted by SEC: 10 Jul 2025, 20:50:14 UTC
Prior SEC filing: 27 May 2025
Next SEC filing: 19 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact

Key filing fact

Christopher Yea filed Form 4 for KalVista Pharmaceuticals, Inc. (KALV) on 10 Jul 2025.

Key facts

This page summarizes Christopher Yea's Form 4 filing for KalVista Pharmaceuticals, Inc. (KALV).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 10 Jul 2025, 20:50.

Change

Previous filing in this sequence was filed on 27 May 2025.
Current net transaction value: -$474,698.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001691102 Primary reporting owner

Yea Christopher

Relationship: CHIEF DEVELOPMENT OFFICER
Address: C/O KALVISTA PHARMACEUTICALS, INC, 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE
Signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact
Signature date: 10 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KALV transaction

Common Stock

Award

Transaction value
Shares: +60,000
Change %: +61%
Price
Shares after: 158,189
Date: 08 Jul 2025
Ownership: Direct
Footnotes: F1, F2

KALV transaction

Common Stock

Sale

Transaction value: $474,698
Shares: -30,250
Change %: -19%
Price: $15.69
Shares after: 127,939
Date: 09 Jul 2025
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Shares earned upon the vesting of a percentage of the performance stock units ("PSUs") granted to the Reporting Person on January 11, 2023. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of performance data metric goals ("Performance Metrics"). 100% of the total number of shares subject to the PSUs vested on July 8, 2025, upon Performance Metrics achieved.

Footnote F2

Each PSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Footnote F3

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.